Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6171
+0.0541 (9.61%)
At close: Sep 26, 2025, 4:00 PM EDT
0.6349
+0.0178 (2.88%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.39M in the quarter ending June 30, 2025, with 8.68% growth. This brings the company's revenue in the last twelve months to $5.32M, down -3.49% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.32M
Revenue Growth
-3.49%
P/S Ratio
1.87
Revenue / Employee
$253,190
Employees
21
Market Cap
61.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PSTV News
- 2 days ago - Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 5 days ago - Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT - GlobeNewsWire
- 9 days ago - Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory - GlobeNewsWire
- 25 days ago - Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - GlobeNewsWire